Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 14, 2008

View Archived Issues

Characterization of gene expression after ABR-215757 therapy in systemic lupus erythematosus

Dose escalation continues in phase II study of voreloxin in platinum-resistant ovarian cancer

TRU-015 retreatment well tolerated, maintains responses in rheumatoid arthritis patients

3SBio files for SFDA approval of NuLeusin in China

Telik enters discovery agreement for musculoskeletal and autoimmune diseases

Avastin provides an additional 4 months of life in patients with lung cancer

Chelsea commences phase I clinical trial of CH-4051

CVBT collaborates with Cardio Neo-Genesis for coronary heart disease candidate

FDA approves low-dose Premarin regimen to treat postmenopausal dyspareunia

Genentech licenses Ex-U.S. rights to GDC-0449 to Roche

DPD-207 active against Staphylococcus aureus in murine infection model

XF-73 activity, resistance examined in Staphylococcus aureus studies

Phase I results confirm tolerability, immunogenicity of cytomegalovirus vaccine

DSTL to evaluate Novacta's lantibiotics as broad-spectrum antiviral treatment

Antigen-pulsed dendritic cell-based vaccine feasible and safe in glioblastoma patients

Antitope and Isu Abxis sign research collaboration in therapeutic monoclonal antibodies

Lexicon announces completion of phase Ib trial of LX-1032 for carcinoid syndrome

Affymax completes enrollment in EMERALD 1 phase III clinical trial of Hematide

FDA designates as complete AMAG's resubmission for ferumoxytol NDA in CKD

Recent Ranbaxy patents disclose novel agents for inflammatory disorders

BioSeek licenses two antiinflammatory peptides from Amylin

IRM reports novel antiobesity compounds in a recent patent

New treatment strategies for transplant rejection described in recent patent lterature

ISTA files NDA with the FDA for Bepreve in allergic conjunctivitis ocular itching

NDA filed for Trelstar 6-month formulation for prostate cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...